BERYL DRUGS LTD.

Beryl Drugs Ltd. has filed its Annual Report for the Financial Year 2025-2026, in compliance with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The report includes the Balance Sheet as of March 31, 2026, and the Statement of Profit and Loss and Cash Flow for the year ended on the same date. It also contains the Board's Report, Corporate Governance Report, and Auditor's Report. The company will hold its 33rd Annual General Meeting on Tuesday, September 29, 2026, at 11:00 AM at Kanchan Palace, Community Hall, Nipania Ring Road, Indore. Key corporate information, including registered office details, secretarial auditors, bankers, listed stock exchanges, board of directors, key managerial personnel, statutory auditors, and registrar and share transfer agents, are provided. The report also details the committees of the board: Audit Committee, Nomination & Remuneration Committee, and Stakeholders’ Relationship Committee.

Beryl Drugs Ltd has issued a notice for its 33rd Annual General Meeting (AGM) to be held on Tuesday, September 29, 2026, at 11:00 A.M. at Kanchan Palace, Community Hall, Nipania Ring Road, Indore. The meeting will cover ordinary business, including the adoption of audited standalone financial statements for the financial year ended March 31, 2026, and the re-appointment of Mr. Sudhir Sethi as a director. Special business includes seeking approval to increase the limit for material related party transactions with m/s. Aminova Infusions Pvt. Ltd. from ₹5.00 crore to ₹8.00 crore for the unexpired tenure of the existing approval.

Beryl Drugs Limited has announced that its Board of Directors, in a meeting held on September 2, 2026, has fixed Tuesday, September 22, 2026, as the cut-off date for determining voting rights for remote e-voting. The company also announced that its 33rd Annual General Meeting (AGM) will be held on Tuesday, September 29, 2026, at 11:00 AM. The book closure period for the AGM is from Wednesday, September 23, 2026, to Tuesday, September 29, 2026, inclusive.

Beryl Drugs Ltd has announced the e-voting dates for its 33rd Annual General Meeting (AGM). The company will provide remote e-voting facilities for its members. The cut-off date for e-voting entitlement is September 7, 2026. Remote e-voting will commence on September 26, 2026, at 9:00 AM IST and conclude on September 28, 2026, at 5:00 PM IST. The AGM itself is scheduled for September 29, 2026, at 11:00 AM. CS Dipika Kataria has been appointed as the scrutinizer for the e-voting process. This announcement is made pursuant to Regulation 44 of SEBI (LODR) Regulations, 2015.

Beryl Drugs Ltd announced the outcome of its Board Meeting held on September 2, 2026. Key decisions included the approval of the Board report, fixation of the date and notice for the 33rd Annual General Meeting (AGM), and the annual book closure dates. The company also set the cut-off date and remote e-voting period for the AGM. Dipika Kataria was appointed as Scrutinizer for the AGM's voting process. Additionally, the board considered and approved a proposal to increase the limit for material related party transactions with M/s. Aminova Infusions Pvt. Ltd. Directors were authorized to file necessary forms under the Companies Act, 2013.

Beryl Drugs Ltd has announced a Board of Directors meeting scheduled for September 2, 2026. The primary agenda items include the approval of the Board report and preparations for the 33rd Annual General Meeting (AGM). Key decisions will involve fixing the AGM date, approving its notice, setting book closure dates, and determining the cut-off date and remote e-voting period. The company will also consider appointing a scrutinizer for e-voting, approving an increase in the limit for material related party transactions with M/s. Aminova Infusions Pvt. Ltd., and authorizing directors to file necessary forms. The meeting will take place at the company's registered office in Indore.

Sudhir Sethi, a promoter of Beryl Drugs Ltd, has acquired 4,809 shares, representing 0.10% of the company's total voting capital. This acquisition increases his total shareholding to 518,928 shares, or 10.24% of the total equity. The transaction was conducted through market transactions. The disclosure was made under SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.

Sudhir Sethi, a promoter of Beryl Drugs Ltd, has acquired 3,000 equity shares, representing 0.06% of the total share capital. This acquisition was made through market transactions. Following the purchase, Sethi's total shareholding in Beryl Drugs increased to 514,119 shares, which constitutes 10.14% of the company's total voting capital. The total equity share capital of the company remains at 50,71,700 shares.

Beryl Drugs Ltd announced its unaudited financial results for the quarter ended June 30, 2026. The Board of Directors approved these results in a meeting held on August 11, 2026. The results are prepared in accordance with Indian accounting standards and SEBI regulations. The company operates in a single segment, the Pharmaceutical Industry. Figures for previous periods have been reclassified where necessary for comparability.

Beryl Drugs Ltd held its Board of Directors meeting on August 11, 2026. The board considered and approved the unaudited financial results for the quarter ended June 30, 2026. Additionally, the Limited Review Report from the auditors for these financial results was taken on record. The company also confirmed the registered office location.